Company Description
Sunshine Biopharma, Inc., a pharmaceutical and nutritional supplement company, focuses on the research and development of anticancer drugs.
The company is developing Adva-27a, a GEM-difluorinated C-glycoside derivative of podophyllotoxin to treat leukemia, lymphoma, testicular, lung, brain, prostate, bladder, colon, ovarian, liver, and other forms of cancers, as well as kills multidrug resistant cancer cells, including pancreatic cancer, breast cancer, small-cell lung cancer, and uterine sarcoma cells; and SBFM-PL4, an anti-coronavirus treatment compound.
It also offers Essential 9, a nutritional supplement tablet; and Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name, as well as develops and markets other science-based nutritional supplements.
The company has a license agreement with the University of Georgia to advance the development of its anti-coronavirus lead compound, SBFM-PL4.
Sunshine Biopharma, Inc. is headquartered in Pointe-Claire, Canada.
Country | CA |
IPO Date | Feb 15, 2022 |
Industry | Drug Manufacturers - Specialty & Generic |
Sector | Healthcare |
Employees | 44 |
CEO | Dr. Steve N. Slilaty Ph.D. |
Contact Details
Address: 6500 Trans-Canada Highway Pointe-Claire, QC CA | |
Website | https://www.sunshinebiopharma.com |
Stock Details
Ticker Symbol | SBFMW |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001402328 |
CUSIP Number | 867781502 |
ISIN Number | US8677815024 |
Employer ID | 20-5566275 |
SIC Code | 8731 |
Key Executives
Name | Position |
---|---|
Dr. Steve N. Slilaty Ph.D. | Chairman, President & Chief Executive Officer |
Camille Sebaaly | Chief Financial Officer & Secretary |
Dr. Abderrazzak Merzouki | Chief Science Officer & Director |
Malek Chamoun | Chief Development Officer |
Robert G. Ferreira | President of Sunshine Bio Investments Inc |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Dec 10, 2024 | 8-K | Current Report |
Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Nov 12, 2024 | 424B4 | Filing |
Nov 07, 2024 | 8-K | Current Report |
Nov 06, 2024 | POS AM | Filing |
Nov 05, 2024 | 10-Q | Quarterly Report |
Oct 23, 2024 | 8-K | Current Report |
Oct 17, 2024 | DEF 14A | Filing |
Sep 10, 2024 | 8-K | Current Report |
Aug 20, 2024 | 10-Q/A | [Amend] Quarterly Report |